Related Experiment Video
Updated: Mar 10, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Pyroglutamic acidosis in association with therapeutic paracetamol use
Robert W Hunter1, Cate Lawson2, Evangelia Galitsiou2
1Royal Infirmary of Edinburgh, Edinburgh, UK and University/BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.
Abstract:
Long-term use of paracetamol (at therapeutic doses) can cause the accumulation of endogenous organic pyroglutamate, resulting in metabolic acidosis with an elevated anion gap. This occurs in the presence of malnutrition, infection, antibiotic use, renal failure and pregnancy. Given the prevalence of these risk factors, this condition is thought to be relatively common in a hospitalised population but is probably significantly underdiagnosed. Prompt recognition is essential because the condition is entirely reversible if the causative agents are withdrawn.Here we describe five cases of pyroglutamic acidosis that we have encountered in a tertiary referral hospital. Together they illustrate the common clinical risk factors and the excellent prognosis, once a diagnosis is made. We describe how a rudimentary acid-base analysis (calculation of the anion gap) usually leads to the diagnosis but how a more nuanced approach may be required in the presence of mixed acid-base disorders.
More Related Videos
Related Concept Videos
Inborn Errors of Metabolism
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Drug toxicity: Drug–Drug Interaction
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Drug Toxicity: Dose-Dependent Reactions
Pharmacokinetics in Pediatric Patients: Drug Metabolism

